Journal article
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
AA Ahmed, D Etemadmoghadam, J Temple, AG Lynch, M Riad, R Sharma, C Stewart, S Fereday, C Caldas, A DeFazio, D Bowtell, JD Brenton
Journal of Pathology | Published : 2010
DOI: 10.1002/path.2696
Abstract
Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 an..
View full abstractGrants
Awarded by US Army Medical Research and Material Command
Funding Acknowledgements
We thank Sarah Hyland, Philip Chambers, Christian Bourne, and Nik Matthews for expert technical assistance. We acknowledge the support of the University of Cambridge, NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and Hutchison Whampoa Ltd. AAA holds a CR-UK Clinician Scientist Fellowship. D Bowtell, G Chenevix-Trench, A deFazio, A Green, D Gertig, and P Webb-The AOCS Management Group-gratefully acknowledge the contributions of the full AOCS Study Group, listed on http://www.aocstudy.org, and express their gratitude to all women who participated in the study. The AOCS was supported by the US Army Medical Research and Material Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the NH&MRC. We also gratefully acknowledge Catherine Emmanuel, Catherine Kennedy, and Yoke-Eng Chiew for samples, and data from the Westmead Gynaecological Oncology Tissue Bank, a member of the Australasian Biospecimens NetworkOncology group funded by the NH&MRC. This work was funded by Cancer Research UK (CR-UK), the Medical Research Council (MRC), and the National Health and Medical Research Council of Australia (NHMRC).